Low Bone Strength Is a Manifestation of Phenylketonuria in Mice and Is Attenuated by a Glycomacropeptide Diet

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Solverson, Patrick ^a   Murali, Sangita G ^a   Litscher, Suzanne J ^b,c   Blank, Robert D ^b,c   Ney, Denise M ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CASEIN; PHENYLALANINE;

ANIMAL EXPERIMENT; ARTICLE; BONE DENSITY; BONE STRENGTH; COGNITIVE DEFECT; DIET; FEMALE; GENE MUTATION; GENOTYPE; GLYCOMACROPEPTIDE DIET; MALE; MOUSE; NONHUMAN; OSTEOGENESIS IMPERFECTA; PHENYLKETONURIA; PROTEIN INTAKE; WILD TYPE;

ABSORPTIOMETRY, PHOTON; ANIMALS; BIOMECHANICS; BONE DENSITY; CASEINS; DIET, PROTEIN-RESTRICTED; ELASTIC MODULUS; FEMALE; FEMUR; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PHENOTYPE; PHENYLALANINE; PHENYLALANINE HYDROXYLASE; PHENYLKETONURIAS;

MUS;

EID: 84866509174     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045165     Document Type: Article

References (48)

1. NIH (2000) Phenylketonuria (PKU): screening and management. NIH Consensus Statement 17: 1-33.
2. MacLeod EL, Ney DM, (2010) Nutritional management of phenylketonuria. Ann Nestle 68: 58-69.
3. de Groot MJ, Hoeksma M, van Rijn M, Slart RH, van Spronsen FJ, (2012) Relationships between lumbar bone mineral density and biochemical parameters in phenylketonuria patients. Mol Genet Metab 105: 566-570.
4. Perez-Duenas B, Cambra FJ, Vilaseca MA, Lambruschini N, Campistol J, et al. (2002) New approach to osteopenia in phenylketonuric patients. Acta Paediatr 91: 899-904.
5. Greeves LG, Carson DJ, Magee A, Patterson CC, (1997) Fractures and phenylketonuria. Acta Paediatr 86: 242-244.
6. Zeman J, Bayer M, Stepan J, (1999) Bone mineral density in patients with phenylketonuria. Acta Paediatr 88: 1348-1351.
7. McMurry MP, Chan GM, Leonard CO, Ernst SL, (1992) Bone mineral status in children with phenylketonuria-relationship to nutritional intake and phenylalanine control. Am J Clin Nutr 55: 997-1004.
8. Allen JR, Humphries IR, Waters DL, Roberts DC, Lipson AH, et al. (1994) Decreased bone mineral density in children with phenylketonuria. Am J Clin Nutr 59: 419-422.
9. Schwahn B, Mokov E, Scheidhauer K, Lettgen B, Schonau E, (1998) Decreased trabecular bone mineral density in patients with phenylketonuria measured by peripheral quantitative computed tomography. Acta Paediatr 87: 61-63.
10. Al-Qadreh A, Schulpis KH, Athanasopoulou H, Mengreli C, Skarpalezou A, et al. (1998) Bone mineral status in children with phenylketonuria under treatment. Acta Paediatr 87: 1162-1166.
11. Koura HM, Abdallah Ismail N, Kamel AF, Ahmed AM, Saad-Hussein A, et al. (2011) A long-term study of bone mineral density in patients with phenylketonuria under diet therapy. Arch Med Sci 7: 493-500.
12. Koch R, Burton B, Hoganson G, Peterson R, Rhead W, et al. (2002) Phenylketonuria in adulthood: a collaborative study. J Inherit Metab Dis 25: 333-346.
13. MacDonald A, (2000) Diet and compliance in phenylketonuria. Eur J Pediatr 159 (Suppl 2):: S136-141.
14. Macdonald A, Daly A, Davies P, Asplin D, Hall SK, et al. (2004) Protein substitutes for PKU: what's new? J Inherit Metab Dis 27: 363-371.
15. Walter JH, White FJ, Hall SK, MacDonald A, Rylance G, et al. (2002) How practical are recommendations for dietary control in phenylketonuria? Lancet 360: 55-57.
16. Enns GM, Koch R, Brumm V, Blakely E, Suter R, et al. (2010) Suboptimal outcomes in patients with PKU treated early with diet alone: revisiting the evidence. Mol Genet Metab 101: 99-109.
17. Laclair CE, Ney DM, MacLeod EL, Etzel MR, (2009) Purification and use of glycomacropeptide for nutritional management of phenylketonuria. J Food Sci 74: E199-206.
18. Ney DM, Gleason ST, van Calcar SC, Macleod EL, Nelson KL, et al. (2009) Nutritional management of PKU with glycomacropeptide from cheese whey. J Inherit Metab Dis 32: 32-39.
19. Van Calcar SC, Macleod EL, Gleason ST, Etzel MR, Clayton MK, et al. (2009) Improved nutritional management of phenylketonuria by using a diet containing glycomacropeptide compared with amino acids. Am J Clin Nutr 89: 1068-1077.
20. Van Calcar SC aND (2012) Food Products Made with Glycomacropeptide, a Low-Phenylalanine Whey Protein, Provide a New Alternative to Amino Acid-Based Medical Foods for Nutrition Management of Phenylketonuria Journal of the Academy of Nutrition and Dietetics In press.
21. McDonald JD, Bode VC, Dove WF, Shedlovsky A, (1990) Pahhph-5: a mouse mutant deficient in phenylalanine hydroxylase. Proc Natl Acad Sci U S A 87: 1965-1967.
22. Solverson P, Murali SG, Brinkman AS, Nelson DW, Clayton MK, et al. (2012) Glycomacropeptide, a low-phenylalanine protein isolated from cheese whey, supports growth and attenuates metabolic stress in the murine model of phenylketonuria. Am J Physiol Endocrinol Metab 302: E885-895.
23. Turner CH, Burr DB, (1993) Basic biomechanical measurements of bone: a tutorial. Bone 14: 595-608.
24. Harding CO, Gillingham MB, Hamman K, Clark H, Goebel-Daghighi E, et al. (2006) Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuria. Gene Ther 13: 457-462.
25. Rogers QR, Harper AE, (1965) Amino acid diets and maximal growth in the rat. J Nutr 87: 267-273.
26. Lopez Franco GE, O'Neil TK, Litscher SJ, Urban-Piette M, Blank RD, (2004) Accuracy and precision of PIXImus densitometry for ex vivo mouse long bones: comparison of technique and software version. J Clin Densitom 7: 326-333.
27. Saless N, Litscher SJ, Lopez Franco GE, Houlihan MJ, Sudhakaran S, et al. (2009) Quantitative trait loci for biomechanical performance and femoral geometry in an intercross of recombinant congenic mice: restriction of the Bmd7 candidate interval. Faseb J 23: 2142-2154.
28. Becker RA, Chambers JM, Wilks AR (1988) The New S Language. Monterey, CA: Wadsworth and Brooks/Cole Advanced Books & Software. 702 p.
29. Mardia KV, Kent JT, Bibby JM (1979) Multivariate Analysis. London: Academic Press. 521 p.
30. Venables WN, Ripley BD (2002) Modern Applied Statistics with S. New York: Springer. 515 p.
31. Saless N, Litscher SJ, Vanderby R, Demant P, Blank RD, (2011) Linkage mapping of principal components for femoral biomechanical performance in a reciprocal HCB-8 × HCB-23 intercross. Bone 48: 647-653.
32. Pearson K, (1901) On lines and planes of closest fit to systems of points in space. Philos Mag 2: 559-572.
33. Frost HM, (2001) From Wolff's law to the Utah paradigm: Insights about bone physiology and its clinical applications. Anatomical Record 262: 398-419.
34. Robey PG, AL B (2008) The Composition of Bone. In: CJ R, editor. Primer on the Metabolic Bone Diseases and Disorders of Bone and Mineral Metabolism. 7th ed. Washington, DC: American Society for Bone and Mineral Research. 32-38.
35. Fratzl P (2008) Collagen: an Introduction. In: Fratzl P, editor. Collagen: Structure and Mechanics. New York: Springer. 1-13.
36. Stein GS, Lian JB, (1993) Molecular mechanisms mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype. Endocr Rev 14: 424-442.
37. Lakes R, (1993) Materials with Structural Hierarchy Nature. 361: 311-315.
38. Blank RD, AL B (2008) Genetic Collagen Diseases. In: Fratzl P, editor. Collagen: Structure and Mechanics. New York: Springer. 447-474.
39. Marini JC, Forlino A, Cabral WA, Barnes AM, San Antonio JD, et al. (2007) Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat 28: 209-221.
40. Sievanen H, Kannus P, Jarvinen TL, (2007) Bone quality: an empty term. PLoS Med 4: e27.
41. Bonadio J, Jepsen KJ, Mansoura MK, Jaenisch R, Kuhn JL, et al. (1993) A murine skeletal adaptation that significantly increases cortical bone mechanical properties. Implications for human skeletal fragility. J Clin Invest 92: 1697-1705.
42. Yannicelli S, Medeiros DM, (2002) Elevated plasma phenylalanine concentrations may adversely affect bone status of phenylketonuric mice. J Inherit Metab Dis 25: 347-361.
43. Modan-Moses D, Vered I, Schwartz G, Anikster Y, Abraham S, et al. (2007) Peak bone mass in patients with phenylketonuria. J Inherit Metab Dis 30: 202-208.
44. Ambroszkiewicz J, Gajewska J, Laskowska-Klita T, (2004) A study of bone turnover markers in prepubertal children with phenylketonuria. Eur J Pediatr 163: 177-178.
45. Millet P, Vilaseca MA, Valls C, Perez-Duenas B, Artuch R, et al. (2005) Is deoxypyridinoline a good resorption marker to detect osteopenia in phenylketonuria? Clin Biochem 38: 1127-1132.
46. Nagasaka H, Tsukahara H, Takatani T, Sanayama Y, Takayanagi M, et al. (2011) Cross-sectional study of bone metabolism with nutrition in adult classical phenylketonuric patients diagnosed by neonatal screening. J Bone Miner Metab 29: 737-743.
47. Roato I, Porta F, Mussa A, D'Amico L, Fiore L, et al. (2010) Bone impairment in phenylketonuria is characterized by circulating osteoclast precursors and activated T cell increase. PLoS One 5: e14167.
48. Leppanen OV, Sievanen H, Jarvinen TL, (2008) Biomechanical testing in experimental bone interventions-May the power be with you. J Biomech 41: 1623-1631.